Floatz Rating
CC45/100
Confidence
Indicative
Sponsor
GlaxoSmithKline
Modality
UNKNOWN
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06885034CT.gov A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Digestive System Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| GSK5764227 (this asset) | GlaxoSmithKline | P1/2 | CC · 45 |
| Capecitabine | China Medical University, China | P3 | BB |
| Sorafenib | Sichuan Cancer Hospital and Research Institute | P3 | BB |
| Irinotecan | Pfizer | P3 | BB |
| Fluorouracilum | Janssen Research & Development, LLC | P3 | B |
| L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))- | Federico II University | P2 | B |
| Linifanib | Abbott | P3 | B |
| Acetylcysteine | German Cancer Research Center | P2 | B |
| Cis-Diamminedichloroplatinum Ii | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P1/2 | B |
+41 more in the Digestive System Neoplasm cohort
Other indications for GSK5764227
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neoplasm | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CapecitabineChina Medical University, ChinaBB
- SorafenibSichuan Cancer Hospital and Research InstituteBB
- IrinotecanPfizerBB
- FluorouracilumJanssen Research & Development, LLCB
- L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-Federico II UniversityB
Citation
Floatz Terminal. GSK5764227 in Digestive System Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/gsk5764227-digestive-system-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →